Skip to content
CNS Clinical Research

Pittsburgh, Pennsylvania

CNS clinical trials in Pittsburgh, PA

56 CNS studies are recruiting participants at sites in Pittsburgh as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Pittsburgh at a glance

  • 56 studies are recruiting at a site in Pittsburgh.
  • By phase: Phase 1 (2), Phase 1/2 (6), Phase 2 (1), Phase 3 (7), Phase 4 (2), No phase (29), Observational (9). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (40), industry (13), government (3).
  • By research area: Depression (24), Parkinson's Disease (11), Schizophrenia (6), ADHD (5), Multiple Sclerosis (4), Epilepsy (3), Migraine (2), Bipolar Disorder (1).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Pittsburgh

Basic details from each study's public record (the 30 most recently updated of 56). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Saint Margaret
    Registry record
    NCT06748222 · updated
  2. Risk and Resilience to Suicide Following Late-Life Spousal Bereavement

    • No phase
    • Ages 60 and older
    • All sexes
    Sponsor
    University of Pittsburgh
    Study site
    University of Pittsburgh (UPMC)
    Registry record
    NCT06191484 · updated
  3. Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments

    • No phase
    • Ages 18 to 55
    • All sexes
    Sponsor
    Marta Peciña, MD PhD
    Study site
    Bellefield Towers
    Registry record
    NCT06976840 · updated
  4. Acoustic Stimulation, Sleep, and Cognitive-Emotional Processes in Young Adults With Anxiety and Depression Symptoms

    • No phase
    • Ages 18 to 25
    • All sexes
    Sponsor
    Michelle Stepan
    Study site
    University of Pittsburgh
    Registry record
    NCT05802004 · updated
  5. An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Pittsburgh
    Study site
    University of Pittsburgh
    Registry record
    NCT07373470 · updated
  6. Sleep Promotion Program Primary Care

    • No phase
    • Ages 12 to 18
    • All sexes
    Sponsor
    University of Pittsburgh
    Study site
    University of Pittsburgh
    Registry record
    NCT06240325 · updated
  7. Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Pittsburgh
    Study site
    University of Pittsburgh
    Registry record
    NCT06978127 · updated
  8. A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

    • No phase
    • Ages 13 to 24
    • All sexes
    Sponsor
    Ksana Health
    Study sites
    STAR Center, Western Psychiatric Institute & Clinic · University of Pittsburgh
    Registry record
    NCT07348666 · updated
  9. Apimostinel + Automated Neurocognitive Training for Depression

    • Phase 2
    • Ages 18 to 60
    • All sexes
    Sponsor
    Rebecca Price
    Study site
    Western Psychiatric Institute and Clinic
    Registry record
    NCT06400121 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Pittsburgh

  1. Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness

    • No phase
    • Ages 18 to 70
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
    Registry record
    NCT05157620 · updated
  2. Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

    • No phase
    • Ages 18 to 40
    • All sexes
    Sponsor
    Fabio Ferrarelli
    Study site
    University of Pittsburgh
    Registry record
    NCT05102929 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Pittsburgh

  1. Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

    • No phase
    • Ages 18 to 40
    • All sexes
    Sponsor
    University of Pittsburgh
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT06081426 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

ADHD studies recruiting in Pittsburgh

  1. The Myelin Disorders Biorepository Project

    • Observational
    • All ages
    • All sexes
    Sponsor
    Children's Hospital of Philadelphia
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT03047369 · updated
  2. AWARE: Management of ADHD in Autism Spectrum Disorder

    • Phase 4
    • Ages 4 to 17
    • All sexes
    Sponsor
    Daniel Coury
    Study site
    University of Pittsburgh
    Registry record
    NCT05916339 · updated
  3. Smartphone-based Intervention for Young Adults With ADHD

    • No phase
    • Ages 18 to 25
    • All sexes
    Sponsor
    Traci Kennedy
    Study site
    University of Pittsburgh
    Registry record
    NCT07654205 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Pittsburgh

  1. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  2. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UPMC Hillman Cancer Center-UPMC ( Site 6904)
    Registry record
    NCT06469944 · updated
  3. Deep Brain Stimulation (DBS) Retrospective Outcomes Study

    • Observational
    • All ages
    • All sexes
    Sponsor
    Boston Scientific Corporation
    Study site
    Allegheny General Hospital
    Registry record
    NCT03664609 · updated
  4. Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    Jorge Gonzalez-Martinez
    Study site
    University of Pittsburgh
    Registry record
    NCT07056361 · updated
  5. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    AHN West Penn Hospital ( Site 6006)
    Registry record
    NCT06952504 · updated
  6. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Allegheny General Hospital
    Registry record
    NCT07174310 · updated
  7. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UPMC Hillman Cancer Center-UPMC ( Site 4904)
    Registry record
    NCT05319730 · updated
  8. Parkinson's Foundation PD GENEration Genetic Registry

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Parkinson's Foundation
    Study site
    Allegheny Health Network
    Registry record
    NCT04994015 · updated
  9. Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UPMC Hillman Cancer Center-UPMC ( Site 8904)
    Registry record
    NCT06445972 · updated
  10. PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

    • Observational
    • Ages 30 and older
    • All sexes
    Sponsor
    Michael J. Fox Foundation for Parkinson's Research
    Study site
    University of Pittsburgh
    Registry record
    NCT04477785 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Pittsburgh

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT03816345 · updated
  2. AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    UniQure Biopharma B.V.
    Study site
    Allegheny Health Network
    Registry record
    NCT06063850 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Epilepsy studies recruiting in Pittsburgh

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    UPMC Comprehensive Epilepsy Center
    Registry record
    NCT05667142 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Migraine studies recruiting in Pittsburgh

  1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Preferred Primary Care Physicians, Inc.
    Registry record
    NCT07645924 · updated
  2. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Preferred Primary Care Physicians, Inc.
    Registry record
    NCT07674654 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Ask about studies near Pittsburgh

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call